Cargando…

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study

BACKGROUND: Only few studies have assessed safety of in utero exposure to glatiramer acetate (GA). Following a previous study assessing the safety of interferon beta (IFNB) pregnancy exposure in multiple sclerosis (MS), we aimed to assess pregnancy and fetal outcomes after in utero exposure to GA, u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giannini, Marta, Portaccio, Emilio, Ghezzi, Angelo, Hakiki, Bahia, Pastò, Luisa, Razzolini, Lorenzo, Piscolla, Elisa, De Giglio, Laura, Pozzilli, Carlo, Paolicelli, Damiano, Trojano, Maria, Marrosu, Maria Giovanna, Patti, Francesco, La Mantia, Loredana, Mancardi, Gianluigi, Solaro, Claudio, Totaro, Rocco, Tola, Maria Rosaria, De Luca, Giovanna, Lugaresi, Alessandra, Moiola, Lucia, Martinelli, Vittorio, Comi, Giancarlo, Amato, Maria Pia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487812/ https://www.ncbi.nlm.nih.gov/pubmed/23088447 http://dx.doi.org/10.1186/1471-2377-12-124

Ejemplares similares

Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study
por: Pastò, Luisa, et al.
Publicado: (2012)

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study
por: Pecori, Chiara, et al.
Publicado: (2014)

The Italian multiple sclerosis register
por: Trojano, Maria, et al.
Publicado: (2018)

A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients
por: Niccolai, Claudia, et al.
Publicado: (2015)

The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population
por: Goretti, Benedetta, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies
por: Bellinvia, Angelo, et al.
Publicado: (2022)

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)
por: Centonze, Diego, et al.
Publicado: (2021)

Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis
por: Fonderico, Mattia, et al.
Publicado: (2021)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study
por: Iaffaldano, Pietro, et al.
Publicado: (2022)

Relevance of Brain Lesion Location to Cognition in Relapsing Multiple Sclerosis
por: Rossi, Francesca, et al.
Publicado: (2012)

Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability
por: Giorgio, Antonio, et al.
Publicado: (2017)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Paolicelli, Damiano, et al.
Publicado: (2009)

Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study
por: Iaffaldano, Pietro, et al.
Publicado: (2012)

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
por: Laroni, Alice, et al.
Publicado: (2014)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo(®))
por: Solla, Paolo, et al.
Publicado: (2010)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study
por: D’Amico, Emanuele, et al.
Publicado: (2016)

EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS
por: Guerrera, Gisella, et al.
Publicado: (2020)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients
por: Zarzuelo-Romero, María José, et al.
Publicado: (2021)

Glatiramer in the treatment of multiple sclerosis
por: Rizvi, Syed A, et al.
Publicado: (2006)

Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2011)

Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies
por: Iaffaldano, Pietro, et al.
Publicado: (2021)

The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis
por: Portaccio, Emilio, et al.
Publicado: (2021)

A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients
por: Gugliandolo, Agnese, et al.
Publicado: (2018)

Dopamine Dysregulation Syndrome in Parkinson’s Disease Patients with Unsatisfactory Switching from Immediate to Extended Release Pramipexole: A Further Clue to Incentive Sensitization Mechanisms?
por: Solla, Paolo, et al.
Publicado: (2013)

Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study
por: Patti, Francesco, et al.
Publicado: (2013)

Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus
por: Filippi, Massimo, et al.
Publicado: (2021)

Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
por: Filippi, Massimo, et al.
Publicado: (2022)

Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
por: Filippi, Massimo, et al.
Publicado: (2022)

Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
por: Sormani, Maria P., et al.
Publicado: (2021)

A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review
por: Parisi, Mosè, et al.
Publicado: (2020)

Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate
por: Bollo, Luca, et al.
Publicado: (2022)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors
por: Amato, Maria Pia, et al.
Publicado: (2019)

Correction: Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors
por: Amato, Maria Pia, et al.
Publicado: (2019)

Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study
por: Bastianello, Stefano, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_r0vckie8bq0lusgppeq0b0oqfs